Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern
- PMID: 31855706
- DOI: 10.1016/j.drugpo.2019.102616
Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern
Abstract
Use of illicit opioids and misuse of prescription opioids are the main causes of drug-related deaths across the world, and the continuing rise in opioid-related mortality, especially affecting North America, Australia and Europe, is a public health challenge. Strategies that may help to decrease the high levels of opioid-related mortality and morbidity and improve care across Europe include risk assessment and interventions to improve the use of opioid analgesics, e.g. prescription drug-monitoring programmes, education on pain management to reduce opioid prescribing, and the implementation of evidence-based primary prevention programmes to reduce the demand for opioids. For patients who develop opioid use disorder (a chronic and relapsing problematic use of opioids that causes clinical impairment or distress), treatment combining opiate receptor full or partial agonist medications for opioid-use disorder (MOUD) with psychosocial interventions is essential. However, in Europe a substantial proportion of the 1.3 million high-risk opioid users (defined as injecting drug use or regular use of opioids, mainly heroin) remain outside of dedicated treatment programmes. More widespread and easier access to MOUD could reduce mortality levels; via approaches such as primary care-led treatment models, and efforts to improve patient retention and adherence to treatment programmes. Other harm-reduction strategies, such as the use of MOUD at optimal doses, the provision of take-home naloxone, the introduction of supervised drug-consumption facilities, and patient education to reduce the risk of overdose may also be beneficial.
Keywords: Death; Medications for opioid-use disorder; Mortality; Opiates; Opioid use disorder; Opioids.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Hannu Alho does not have any direct conflicts of interests but acknowledges that through the University of Helsinki he manages funds from or gives expert advice to Indivior. Maurice Dematteis has provided expert advice and received fees to give lectures to Bouchara-Recordati Laboratories, Camurus and Indivior, and was co-investigator for two Ethypharm studies (ALPADIR, ALPADE). Danilo Lembo was an employee of Indivior UK Ltd during the conduct of this work. Icro Maremmani is president of the European Opiate Addiction Treatment Association (EUROPAD) and president of the World Federation for the Treatment of Opioid Dependence (WFTOD) non-governmental organisation with Special Consultative Status to the United Nations Economic and Social Council (ECOSOC), and has served as board member for CT Sanremo, D&A Pharma, Indivior, Lundbeck, Molteni and Mundipharma. Carlos Roncero has received fees to give lectures for Astra, Exceltis, Ferrer-Brainfarma, Gilead, GSK, Indivior, Janssen-Cilag, Lundbeck, MSD, Otsuka, Pfizer, Sanofi and Servier. He has received financial compensation for his participation as a board member of Exceltis, Gilead, Indivior, Janssen-Cilag, Lundbeck, Martindale, MSD and Mundipharma. He has carried out the PROTEUS project, which was funded by a grant from Indivior/Reckitt-Benckiser. He received two medical education grants from Gilead. Lorenzo Somaini has received fees to give lectures for Indivior, Gilead, Camurus, and has served as a board member for Indivior, Gilead, MSD. Michael Soyka has worked as a consultant or received grants from Indivior, Servier, Camurus and Novartis over the past five years.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
